Search Results - "Sheean, G."

Refine Results
  1. 1

    The pathophysiology of spasticity by Sheean, G.

    Published in European journal of neurology (01-05-2002)
    “…Spasticity is only one of several components of the upper motor neurone (UMN) syndrome, known collectively as the `positive' phenomena, that are characterized…”
    Get full text
    Journal Article
  2. 2

    Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement by Sheean, G., Lannin, N. A., Turner-Stokes, L., Rawicki, B., Snow, B. J.

    Published in European journal of neurology (01-08-2010)
    “…Upper limb spasticity affecting elbow, wrist, and finger flexors can be safely and effectively reduced with injections of botulinum toxin type‐A (BoNT‐A). It…”
    Get full text
    Journal Article Conference Proceeding
  3. 3

    International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments - introduction by Esquenazi, A., Novak, I., Sheean, G., Singer, B. J., Ward, A. B.

    Published in European journal of neurology (01-08-2010)
    “…Botulinum neurotoxin (BoNT) is most commonly used to reduce focal over‐activity in skeletal muscle, although newer indications such as management of drooling,…”
    Get full text
    Journal Article
  4. 4

    An electrophysiological study of the mechanism of fatigue in multiple sclerosis by SHEEAN, G. L, MURRAY, N. M. F, ROTHWELL, J. C, MILLER, D. H, THOMPSON, A. J

    Published in Brain (London, England : 1878) (01-02-1997)
    “…Fatigue is a common and disabling symptom in multiple sclerosis but is poorly understood. We investigated 'physiological' fatigue in 21 patients with multiple…”
    Get full text
    Journal Article
  5. 5

    Botulinum toxin assessment, intervention and aftercare for paediatric and adult niche indications including pain: international consensus statement by Rawicki, B., Sheean, G., Fung, V. S. C., Goldsmith, S., Morgan, C., Novak, I.

    Published in European journal of neurology (01-08-2010)
    “…Evidence is emerging for the use of botulinum neurotoxin type‐A (BoNT‐A) for niche indications including pain independent of spasticity. Pain indications such…”
    Get full text
    Journal Article Conference Proceeding
  6. 6

    Changes in the balance between motor cortical excitation and inhibition in focal, task specific dystonia by Ridding, M C, Sheean, G, Rothwell, J C, Inzelberg, R, Kujirai, T

    “…Transcranial magnetic stimulation has been used in a double pulse paradigm to investigate the excitability of intrinsic motor cortical circuits in 15 patients…”
    Get full text
    Journal Article
  7. 7

    The external anal sphincter operates at short sarcomere length in humans by Mittal, R. K., Sheean, G., Padda, B. S., Lieber, R., Raj Rajasekaran, M.

    Published in Neurogastroenterology and motility (01-07-2011)
    “…Background  The length at which a muscle/sarcomere operates in vivo (operational length) and the length at which it generates maximal stress (optimal length)…”
    Get full text
    Journal Article Conference Proceeding
  8. 8

    Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? by Sheean, G L

    Published in Current opinion in neurology (01-12-2001)
    “…Clinical experience seems to indicate that botulinum toxin injections can, in selected patients with upper motor neurone syndrome, reduce spasticity and…”
    Get full text
    Journal Article
  9. 9

    Evaluating the role of botulinum toxin in the management of focal hypertonia in adults by Richardson, Davina, Sheean, Geoff, Werring, David, Desai, Margi, Edwards, Susan, Greenwood, Richard, Thompson, Alan

    “…OBJECTIVES To investigate the effects of EMG guided botulinum toxin (BTX-A) on impairment and focal disability in adults presenting with focal hypertonia…”
    Get full text
    Journal Article
  10. 10

    Abnormal motor unit synchronization of antagonist muscles underlies pathological co-contraction in upper limb dystonia by FARMER, S. F, SHEEAN, G. L, MAYSTON, M. J, ROTHWELL, J. C, MARSDEN, C. D, CONWAY, B. A, HALLIDAY, D. M, ROSENBERG, J. R, STEPHENS, J. A

    Published in Brain (London, England : 1878) (01-05-1998)
    “…The aim of this study was to examine the pathophysiological mechanisms underlying co-contraction in patients with dystonia (n = 6) and writer's cramp (n = 5)…”
    Get full text
    Journal Article
  11. 11

    Anchor universities as leaders in the well-being movement: lessons learned from the University of California Healthy Campus Network & pandemic by Slusser, Wendelin, Schmidt, L, Imbery, C, Watson, T, Moin, T, Chobdee, J, Alas, S, Ezenwugo, S, Sheean-Remotto, G

    Published in Journal of American college health (07-06-2024)
    “…The University of California (UC) Healthy Campus Network (HCN) is a robust network of diverse coalitions across 10 UC campuses, 5 UC teaching hospitals, and UC…”
    Get full text
    Journal Article
  12. 12

    Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp a PET study by CEBALLOS-BAUMANN, A. O, SHEEAN, G, PASSINGHAM, R. E, MARSDEN, C. D, BROOKS, D. J

    Published in Brain (London, England : 1878) (01-04-1997)
    “…Previous H2(15)O PET activation studies on patients with idiopathic torsion dystonia (ITD) have shown overactive striatum and frontal accessory areas and…”
    Get full text
    Journal Article
  13. 13

    An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis by SHEEAN, G. L, MURRAY, N. M. F, ROTHWELL, J. C, MILLER, D. H, THOMPSON, A. J

    Published in Brain (London, England : 1878) (01-05-1998)
    “…We studied the electrophysiological parameters of motor performance in eight patients with multiple sclerosis and troublesome fatigue, before and after…”
    Get full text
    Journal Article
  14. 14

    Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A by Houser, M K, Sheean, G L, Lees, A J

    “…OBJECTIVE A previous study of botulinum toxin type F (BTX-F) treatment for torticollis had shown a dose of 520 MU to be effective, but for a much shorter…”
    Get full text
    Journal Article Conference Proceeding
  15. 15

    Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis by Baek, William S, Bashey, Asad, Sheean, Geoffrey L

    “…Rituximab depletes B cells by binding to the CD20 molecule and initiating complement-dependent cytolysis or antibody-dependent cell-mediated cytotoxicity. 1…”
    Get full text
    Journal Article
  16. 16

    Pain and remote weakness in limbs injected with botulinum toxin A for writer's cramp by Sheean, G L, Murray, N M, Marsden, C D

    Published in The Lancet (British edition) (15-07-1995)
    “…We describe two cases of a syndrome resembling neuralgic amyotrophy that occurred in limbs injected with botulinum toxin for writer's cramp. In both cases, one…”
    Get more information
    Journal Article
  17. 17
  18. 18

    Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A by Sheean, G L, Lees, A J

    “…Two reports have shown a Japanese preparation of botulinum toxin type F (BTX-F) to be an effective alternative for patients with torticollis who develop…”
    Get full text
    Journal Article Conference Proceeding
  19. 19

    Botulinum toxin treatment of adult spasticity : A benefit-risk assessment by SHEEAN, Geoffrey

    Published in Drug safety (2006)
    “…Injections of botulinum toxin have revolutionised the treatment of focal spasticity. Before their advent, the medical treatment for focal spasticity involved…”
    Get full text
    Journal Article
  20. 20